Even more interestingly, targeting BAFF therapies (i.e., belimumab) are available and approved for autoimmune disorders characterized by BAFF overproduction, mainly SLE [15] and recently in patients with lupus nephritis [16] as has been demonstrated by methods of immunohistochemistry [14] and RNAseq [17] of renal biopsies, suggesting that giving anti-BAFF drugs may be a future strategy to treat patients with NS. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.